This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
All antipsychotic drugs approved in the past 70 years have shared one mechanism: blocking dopamine D2 receptors. This approach reduces positive symptoms (hallucinations, delusions) but does little for the negative symptoms (social withdrawal, flat affect, loss of motivation) or cognitive impairment that drive most of schizophrenia's disability burden. KarXT (xanomeline-trospium), approved by the FDA in September 2024, is the first antipsychotic with a fundamentally different mechanism — muscarinic acetylcholine receptor agonism — and does not block dopamine at all. This breakthrough is opening an entirely new chapter in schizophrenia research.
KarXT: The First Non-Dopamine Antipsychotic
Xanomeline is a muscarinic M1/M4 receptor agonist originally developed at Eli Lilly in the 1990s. Early clinical trials found it reduced positive and negative schizophrenia symptoms but caused severe gastrointestinal side effects (nausea, vomiting, excessive sweating) via peripheral muscarinic receptor activation — the drug was abandoned. Karuna Therapeutics had the insight to combine xanomeline with trospium chloride, a muscarinic antagonist that does not cross the blood-brain barrier. Trospium blocks the peripheral side effects while xanomeline's central M1/M4 agonism remains active.
The EMERGENT-1 and EMERGENT-2 Phase 3 trials showed KarXT (now marketed as Cobenfy, Bristol Myers Squibb after the Karuna acquisition) significantly reduced total PANSS scores (the standard schizophrenia symptom scale) compared to placebo — by 9.6–11.6 points. Critically, it improved both positive and negative symptom subscales. No weight gain, no significant movement disorders (extrapyramidal symptoms), and no metabolic side effects were observed — the typical burden of D2-blocking antipsychotics. FDA approved Cobenfy in September 2024 for adults with schizophrenia.
Muscarinic Mechanism: Why M1/M4 Targets Schizophrenia
The muscarinic M1 and M4 receptors are heavily expressed in the prefrontal cortex, hippocampus, and striatum — brain regions central to cognitive function and the regulation of dopamine neurotransmission. Post-mortem studies in schizophrenia brains have consistently found reduced muscarinic receptor expression, suggesting cholinergic deficit as a core pathological feature.
M1 agonism in the prefrontal cortex enhances cognitive function by improving working memory circuits. M4 agonism in the striatum indirectly reduces dopamine release — potentially explaining KarXT's antipsychotic effect without direct D2 blockade. This mechanism may explain why the drug helps both positive symptoms (via dopamine modulation) and negative/cognitive symptoms (via direct cortical M1 effects) — the holy grail of schizophrenia pharmacology that D2 antagonists have never achieved.
Multiple follow-on muscarinic programs are now entering clinical development: emraclidine (Eli Lilly, M4-selective agonist) is in Phase 2 trials; other M1/M4 agonists from J&J and AbbVie are in preclinical to early clinical stages.
Targeting Negative Symptoms and Cognitive Impairment
Negative symptoms — blunted affect, alogia (poverty of speech), avolition, asociality, anhedonia — and cognitive impairment (working memory, processing speed, executive function) are the primary drivers of functional disability in schizophrenia and are poorly addressed by all current treatments. These represent the major unmet need in schizophrenia drug development.
Roluperidone (MIN-101): A sigma-2 and 5-HT2A receptor antagonist specifically targeting negative symptoms. Phase 3 CYPRESS trial failed its primary endpoint in the full population but showed benefit in patients with predominantly negative symptoms. A refined Phase 3 is enrolling in this enriched population.
Iclepertin (BI 425809): A GlyT1 inhibitor that increases glycine availability at NMDA receptors — the glutamate hypothesis of schizophrenia posits that NMDA receptor hypofunction drives cognitive impairment. Phase 2 results showed a 1.1-point improvement on the MATRICS Consensus Cognitive Battery vs. 0.1 for placebo — modest but statistically significant. Phase 3 CONNICS trial results are expected in 2025–2026.
Luvadaxistat (TAK-831): Another D-amino acid oxidase inhibitor that raises D-serine levels to potentiate NMDA activity. Phase 2 data showed improved cognitive function in schizophrenia patients and is advancing to Phase 3.
Long-Acting Injectables and Adherence
Medication non-adherence in schizophrenia contributes heavily to relapse and hospitalization. Long-acting injectable (LAI) antipsychotics administered monthly, bimonthly, or quarterly address this by removing the need for daily pill-taking. The FIRST trial showed that patients randomized to LAI aripiprazole as their initial treatment had significantly better outcomes than those starting oral medication — suggesting LAIs may be underutilized as early treatment.
In 2026, a once-every-six-month injectable (paliperidone palmitate 12-month formulation, Invega Hafyera) is an available option. A once-yearly injectable is in development at Teva. The field is also exploring whether LAI antipsychotics reduce the risk of early psychosis converting to full schizophrenia in ultra-high-risk individuals — trials are underway.
Key Takeaways
- KarXT (Cobenfy) is the first antipsychotic in 70 years to work without D2 blockade — its muscarinic M1/M4 mechanism improves both positive and negative symptoms without metabolic or movement side effects.
- Emraclidine and other M4-selective agonists are in Phase 2, building on KarXT's proof of concept for the muscarinic pathway.
- NMDA receptor-enhancing drugs (iclepertin, luvadaxistat) are in Phase 2/3 targeting cognitive impairment — the largest unmet need in schizophrenia.
- Long-acting injectables are underutilized relative to evidence; the FIRST trial supports their use as first-line therapy to improve adherence.
- Roluperidone is being re-evaluated in patients with predominantly negative symptoms — a targeted approach for the most refractory aspect of schizophrenia.